A series of initial public offering plans unveiled by South Korean biopharma firms, notably Orum Therapeutics Inc., is raising hopes of a recovery in the general funding situation in the sector.
After an idle period on Kosdaq which saw D&D Pharmatech’s KRW36bn ($26m) offering as the sole notable IPO in the sector in the first half, and a continued poor funding situation,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?